Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Cancer Profiling Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
The latest in-depth cancer profiling market research report has been added to the repository, illuminating the substantial growth in the industry set to rise from $11.93 billion in 2023 to an estimated $13.4 billion by 2024, a noteworthy CAGR of 12.3%. This surge emphasizes the escalating need for advanced profiling technologies and precision therapeutic strategies in response to the rising cancer incidence worldwide.
Navigating through the compelling growth factors, the study highlights the integration of artificial intelligence in diagnostic methodologies, increasing global partnerships in cancer research, and the expanding landscape of liquid biopsy technologies. These pivotal elements are projected to catapult the cancer profiling sector to a staggering $20.35 billion by 2028, blossoming at a consistent CAGR of 11.0%.
With an in-depth geographical analysis, North America emerges as the dominant region in the cancer profiling market as of 2023, fostering groundbreaking healthcare innovations and clinical methodologies. The report spans across vital territories, including Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa, presenting a comprehensive evaluation of the regional contributions to this thriving market.
The research deeply dissects key technologies employed in cancer profiling, such as immunoassays, PCR (polymerase chain reaction), NGS (next-generation sequencing), microarrays, and in-situ hybridization. These pivotal tools stand at the forefront in tackling prevalent cancers including breast, lung, colorectal, and prostate cancer, revolutionizing screening, diagnostics, and prognostics.
Furthermore, the publication elucidates strategies adopted by major players that directly impact the landscape of cancer diagnostics and treatment. Innovations like Roche's AVENIO Edge System mark a significant stride in automated NGS technologies, while Qiagen's recent launch of the Thera screen EGFR Plus RGQ PCR Kit represents a leap in precision diagnostics for non-small cell lung cancer.
Technological Innovations Charting the Course for Cancer Profiling's Future
The report accentuates the dynamic infrastructural advancements that underpin the cancer profiling industry. From multisector collaborations to the roll-out of advanced diagnostic test kits and early-detection strategies, the analysis provides an incisive look into the transformative efforts reshaping cancer care.
- Spotlight on Liquid Biopsy and Genomic Profiling Methods
- Implications of Regulatory Frameworks on Precision Medicine
- Insight into Developing Single-Cell Sequencing Techniques
- Overview of Immuno-profiling in Cancer Research and Therapy
The comprehensive cancer profiling market report serves as an instrumental asset for stakeholders, providing a panoramic view of industry trends, opportunities, and the projected trajectory for future growth. This includes crucial market statistics and a detailed segment-wise analysis, enabling entities within the medical community to make informed decisions and strategize effectively.
The significance of cancer profiling remains paramount as healthcare systems worldwide grapple with the rising tide of cancer incidence. This latest publication sheds light on the profound implications for treatment modalities and patient outcomes, reinforcing the value of research and innovation in the quest to conquer cancer.
The cancer profiling market research report is an essential resource for anyone looking to understand the undercurrents shaping oncological diagnostics and the wider implications for global health services.
A selection of companies mentioned in this report includes
- Illumina Inc.
- Qiagen NV
- NeoGenomics Inc.
- Sysmex Corporation
- HTG Molecular Diagnostics Inc.
- Caris Life Sciences
- NanoString Technologies Inc.
- Guardant Health Inc.
- Foundation Medicine Inc.
- Roche Diagnostics Corporation
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Genscript Biotech Corporation
- Tempus Labs Inc.
- Hologic Inc.
- Predictive Oncology Inc.
- Abbott Laboratories
- Agilent Technologies Inc.
- PerkinElmer Inc.
- Siemens Healthineers
- Genomic Health Inc.
- Natera Inc.
- ArcherDX Inc.
- Personal Genome Diagnostics Inc.
- Enzo Biochem Inc.
- Cancer Genetics Inc.
- OncoDNA SA
- Ribomed Biotechnologies Inc.
- Biocartis Group NV
- N-of-One Inc.
- Cynvenio Biosystems Inc.
- Inivata Ltd.
- Burning Rock Biotech Limited
- PathAI Inc.
- GENEWIZ Inc.
- Genoptix Inc.
- Oncomine Dx Target Test
- OmniSeq Comprehensive
- Resolution Bioscience
- OncoCyte Corporation
For more information about this report visit https://www.researchandmarkets.com/r/clsfyf
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
